Apimeds Pharmaceuticals US (APUS) Total Current Liabilities (2023 - 2025)

Apimeds Pharmaceuticals US has reported Total Current Liabilities for 3 years, with the latest figure at $10.7 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities rose 945.21% year-over-year to $10.7 million; the trailing twelve-month figure through Dec 2025 stood at $10.7 million (up 945.21% YoY), and the FY2025 full-year result was $10.7 million, up 945.21% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $10.7 million, up from $1.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $10.7 million in Q4 2025, with the low at $123316.0 in Q4 2023.
• Historically, Total Current Liabilities has averaged $2.6 million across 3 years, with a median of $1.1 million in 2024.
• Annual changes were most pronounced in 2024 — Total Current Liabilities soared 730.66% — and 2025, when it surged 945.21%.
• Apimeds Pharmaceuticals US's Total Current Liabilities stood at $123316.0 in 2023, then soared by 730.66% to $1.0 million in 2024, then surged by 945.21% to $10.7 million in 2025.
• The last three Total Current Liabilities figures came in at $10.7 million (Q4 2025), $1.1 million (Q3 2025), and $809002.0 (Q2 2025), per Business Quant data.